Delving into the Latest Updates on Qingdao Growful Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Nervous System Diseases

Herbal medicine

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	2
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Herbal medicine	3
Small molecule drug	1

[Translation] A single-center, randomized, open-label, two-dose, fasting and postprandial, single-dose, two-period, double-crossover bioequivalence study of rosuvastatin capsules developed by Qingdao Guofeng Pharmaceutical Co., Ltd. of Shanghai Pharmaceutical Group and the original reference preparation in healthy Chinese subjects

以上海医药集团青岛国风药业股份有限公司研制的罗沙司他胶囊（规格：50 mg）为受试制剂，持证商为珐博进（中国）医药技术开发有限公司的罗沙司他胶囊（商品名：爱瑞卓®，规格：50 mg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

Rosuvastatin capsules (specification: 50 mg) developed by Qingdao Guofeng Pharmaceutical Co., Ltd. of Shanghai Pharmaceutical Group were used as the test preparation, and Rosuvastatin capsules (trade name: Aeridro®, specification: 50 mg) of FibroGen (China) Pharmaceutical Technology Development Co., Ltd. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date03 Aug 2024

Sponsor / Collaborator

Qingdao Growful Pharmaceutical Co. Ltd.

CTR20210171 / RecruitingPhase 4

养心氏片对比曲美他嗪对PCI术后患者运动耐量的影响：一项前瞻性、多中心、随机、双盲双模拟、活性药物对照临床研究

[Translation] Effects of Yangxinshi tablets versus trimetazidine on exercise tolerance in patients after PCI: a prospective, multicenter, randomized, double-blind, double-dummy, active drug-controlled clinical study

该项研究为国内多中心、前瞻性的非劣效临床研究，试验目的是评价中成药养心氏片对比曲美他嗪对药物治疗24周后PCI患者心脏康复的影响。

[Translation]

This study is a domestic multicenter, prospective, non-inferiority clinical study. The purpose of the trial is to evaluate the effect of the Chinese patent medicine Yangxinshi tablets compared with trimetazidine on cardiac rehabilitation in PCI patients after 24 weeks of drug treatment.

Start Date01 Aug 2019

Sponsor / Collaborator

Qingdao Growful Pharmaceutical Co. Ltd.

100 Clinical Results associated with Qingdao Growful Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Qingdao Growful Pharmaceutical Co. Ltd.

Login to view more data

2

Literatures (Medical) associated with Qingdao Growful Pharmaceutical Co. Ltd.

Shanghai Yiyao

Optimal conditions for the decolorization of oligosaccharide extract from Rehmannia

Author: Zhang, Cong ; Zhao, Junmei ; Wang, Jing ; Hong, Yi

Effects of the amount of activated carbon, temperature, adsorption time and stirring speed on the decolorization of oligosaccharide extract from Rehmannia were investigated by orthogonal experimentsThe optimal conditions were as follows, 6% of the amount of activated carbon (weight/weight, activated carbon/Rehmannia) and stirred at 80 r/min and 80°C for 30 min.The average content of stachyose and the average removal rate of impurities were 62.97% and 82.33%, resp.

Zhongguo Haiyang Yaowu

Determination of contents of aconitine in Shenhailong capsules by RP- HPLC

Author: Guo, Shuxia ; Zhan, Wei ; Xie, Yahua

The aim of this paper is to establish a RP-HPLC method for determination of aconitine in Shenhailong capsules.Zorbax SB-C₁₈ column (4.6 mm × 250 mm, 5 μm) was used, with 60:40:0.1, as the mobile phase.The flow rate was 1.0 mL/min^-1 and the column temperature was at 30°.The detection wavelength was 240 nm.Aconitine concentration presented a good linear range of 0.04 × 10^-3 to 4 × 10^-3 g/L^-1 (r = 0.9999). with the average recovery of 98.4%, and RSD 1.0%.The method was accurate, nice in reproducibility and with few interference.It could be used for quality control of Shenhailong capsules.

100 Deals associated with Qingdao Growful Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Qingdao Growful Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Yinqiao Jiedu Granules	Common Cold More	Approved
Xiaoer Feire Kechuan Granules	Common Cold More	Approved
Polysaccharide Iron Complex	-	Approved
YangXinShi	Myocardial Infarction More	Approved